Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients

Mario Roselli; Fiorella Guadagni; Oreste Buonomo; Augusto Belardi; Vincenzo Vittorini; Andrea Cavazzana; Luigi Giusto Spagnoli; Cesidio Cipriani; Carlo Umberto Casciani

Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients

Mario Roselli, Fiorella Guadagni, Oreste Buonomo, Augusto Belardi, Vincenzo Vittorini, Andrea Cavazzana, Luigi Giusto Spagnoli, Cesidio Cipriani, Carlo Umberto Casciani

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery™ (RIGS®) with an anti-CEA F023C5 F(Ab′)₂ MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.

Original language	English
Pages (from-to)	883-890
Number of pages	8
Journal	Anticancer Research
Volume	16
Issue number	2
Publication status	Published - 1996

Keywords

I-FO23C5
Anti-CEA MAb
Carcinoembryonic antigen
Colorectal cancer
Radioimmunoguided surgery

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients'. Together they form a unique fingerprint.

Cite this

Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients. / Roselli, Mario; Guadagni, Fiorella; Buonomo, Oreste; Belardi, Augusto; Vittorini, Vincenzo; Cavazzana, Andrea; Spagnoli, Luigi Giusto; Cipriani, Cesidio; Casciani, Carlo Umberto.

In: Anticancer Research, Vol. 16, No. 2, 1996, p. 883-890.

Research output: Contribution to journal › Article › peer-review

Roselli, Mario ; Guadagni, Fiorella ; Buonomo, Oreste ; Belardi, Augusto ; Vittorini, Vincenzo ; Cavazzana, Andrea ; Spagnoli, Luigi Giusto ; Cipriani, Cesidio ; Casciani, Carlo Umberto. / Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients. In: Anticancer Research. 1996 ; Vol. 16, No. 2. pp. 883-890.

@article{cc755ae4aba04493821e2ea9870a971f,

title = "Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients",

abstract = "Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery{\texttrademark} (RIGS{\textregistered}) with an anti-CEA F023C5 F(Ab′)2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.",

keywords = "I-FO23C5, Anti-CEA MAb, Carcinoembryonic antigen, Colorectal cancer, Radioimmunoguided surgery",

author = "Mario Roselli and Fiorella Guadagni and Oreste Buonomo and Augusto Belardi and Vincenzo Vittorini and Andrea Cavazzana and Spagnoli, {Luigi Giusto} and Cesidio Cipriani and Casciani, {Carlo Umberto}",

year = "1996",

language = "English",

volume = "16",

pages = "883--890",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2",

}

TY - JOUR

T1 - Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients

AU - Roselli, Mario

AU - Guadagni, Fiorella

AU - Buonomo, Oreste

AU - Belardi, Augusto

AU - Vittorini, Vincenzo

AU - Cavazzana, Andrea

AU - Spagnoli, Luigi Giusto

AU - Cipriani, Cesidio

AU - Casciani, Carlo Umberto

PY - 1996

Y1 - 1996

N2 - Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery™ (RIGS®) with an anti-CEA F023C5 F(Ab′)2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.

AB - Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery™ (RIGS®) with an anti-CEA F023C5 F(Ab′)2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.

KW - I-FO23C5

KW - Anti-CEA MAb

KW - Carcinoembryonic antigen

KW - Colorectal cancer

KW - Radioimmunoguided surgery

UR - http://www.scopus.com/inward/record.url?scp=0029898693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029898693&partnerID=8YFLogxK

M3 - Article

C2 - 8687145

AN - SCOPUS:0029898693

VL - 16

SP - 883

EP - 890

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -